Oxford spin-out Alethio Therapeutics raises €80.46 million Series A to advance targeted blood cancer therapies

Alethio Therapeutics (Alethio), an Abingdon-on-Thames-based biopharmaceutical company developing next-generation therapies for myeloproliferative neoplasms (MPNs), has announced the completion of an oversubscribed €80.46 million ($90 million/£67 million) Series A financing.

The round was co-led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises, with additional support from Cancer Research Horizons and the University of Oxford. As part of the financing, Graziano Seghezzi, Managing Partner…